Huberman Lab

Dr. Matthew Johnson: Psychedelics for Treating Mental Disorders

248 snips
Sep 20, 2021
In this enlightening discussion, Dr. Matthew Johnson, a leading researcher at Johns Hopkins, explores the groundbreaking potential of psychedelics like psilocybin and MDMA in treating mental health disorders. He details the clinical trials underway in his lab and explains the therapeutic framework necessary for success. Dr. Johnson also tackles common misconceptions, safety issues, and the evolving legal landscape surrounding psychedelics, emphasizing their transformative power in psychiatric medicine. His insights illuminate how these substances could redefine mental health care.
Ask episode
AI Snips
Chapters
Books
Transcript
Episode notes
INSIGHT

Defining Psychedelics

  • "Psychedelic" isn't a strict pharmacological term, encompassing various classes.
  • It refers to substances profoundly altering reality and sense of self.
ANECDOTE

Altered Reality

  • A research volunteer seemed to believe she could dive through a painting.
  • This highlights altered space-time perception under psychedelics' influence.
INSIGHT

Serotonin, Glutamate, and Psychedelic Effects

  • Classic psychedelics activate serotonin 2A receptors, increasing glutamate.
  • This might explain experiential overlaps with NMDA antagonists like ketamine.
Get the Snipd Podcast app to discover more snips from this episode
Get the app